• Therapeutic efficacy of Proteflazid, suppository among the patients with genitourinary viral-bacterial infection 
To content

Therapeutic efficacy of Proteflazid, suppository among the patients with genitourinary viral-bacterial infection 

HEALTH OF WOMAN. 2016.2(108):162–166; doi 10.15574/HW.2016.108.162 
 

Therapeutic efficacy of Proteflazid, suppository among the patients with genitourinary viral-bacterial infection 
 

Benyuk V. O., Grinevich O. I., Usevich I. A., Sikachova I. S., Shepetko M. V.

National medical University named after O. O. Bogomolets, Kyiv

«Scientific-production company «Ekofarm» LLC, Kyiv 
 

The article reports of Phase-II clinical trial results for Proteflazid®, suppository, among the patients with genitourinary viral-bacterial infection. It had been shown high therapeutic efficacy Proteflazid®, suppositories with comparable values for Proteflazid®, drops (in the form of vaginal tampon with the drug solution). Presented data allowed to draw conclusion that Proteflazid®, suppositories can be recommended for implementation in clinical practice as a drug with high efficacy and good tolerability for the treatment of genitourinary viral-bacterial infection.


Key words: Proteflazid®, suppository; Proteflazid, drops; Deschampsia caespitosa L.; Calamagrostis epigeios L.; flavonoids; viral-bacterial mixed infection, Herpes genitalis, Chlamydia


REFERENCES

1. Adler MW. 1996. Sexually transmitted diseases control in developing countries. Genitourin. Med. 72(2):83–88.

2. Alexander LL, Ireiman K, Clarc P. 1996. A national survey of nurse practitioner chlamydia knowledge and treatment practices of female patients. Nurse Practitioner 21(5);48:51–54. http://dx.doi.org/10.1097/00006205-199605000-00004

3. Bacon ТН, Levin MJ, Leary JJ et al. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clinical Microbiology Reviews 16;l:114–128.

4. Leung DT, Sacks SL. 2000. Current Recommendations for the treatment of genital herpes. Drugs. 60(6):1329–1352. http://dx.doi.org/10.2165/00003495-200060060-00007

5. Looker KJ, Garnett GP. 2005. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sexually Transmitted Infections 81:103–107. http://dx.doi.org/10.1136/sti.2004.012039; PMid:15800084 PMCid:PMC1764655

6. Glazkova LK, Gerasimova NM. 1998. Condition factors of nonspecific protection of women with chlamydia organism. Journal of Dermatology and Venereology 1: 7.

7. Gomberg MA, Soloviev AM, Chernousov AD. 2000. Rationale for immunotherapy in the treatment of recurrent urogenital chlamydiosis. STI 2: 30-35.

8. Recommendations for the treatment of genital herpes (adapted from Guidelines for the Management of Genital Herpes in New Zealand 7th Ed -.. 2004). Women's Health. 2006, 3 (27): 167-172.